Neko Health Valuation, Funding & Investors

Ro is a New York-headquartered telehealth company launched in 2017. The platform offers men's health treatments through Roman, women's health via Rory, weight management with Sequence, and fertility care under Ro Fertility. Ro integrates virtual consultations with licensed providers, at-home diagnostics, and direct medication delivery from FDA-approved pharmacies in all 50 states. Its infrastructure includes proprietary fulfillment centers in Tempe and Dallas processing millions of prescriptions annually. Ro expanded into primary care with Ro Mind for mental health and Ozlo for gastrointestinal treatments.

Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.

Hangzhou Diagens Biotechnology Co Ltd is a medical devices company focusing on developing medical imaging products and services. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping which the company intends to sell in China and globally as a customized computer pre-installed with the software.

Diasorin develops and manufactures a broad portfolio of in vitro diagnostics used for detecting pathogens and contamination of samples from the human body, as well as used in industrial settings such as food and water contamination testing. The company operates three segments: immunodiagnostics (66% of sales), molecular diagnostics (17%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2024, it accounted for only 2% of total sales.

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Seoul-based Olive Healthcare develops noninvasive near-infrared devices for abdominal fat measurement and breast cancer screening. Employing AI algorithms and big data, its portable scanners provide customized diagnostic reports without radiation.

Sword Health is a Lisbon-headquartered digital therapeutics company offering AI-guided physical therapy for musculoskeletal and pelvic floor conditions. Patients access virtual sessions via app with motion-tracking sensors and clinician oversight. The platform supports remote recovery programs for back pain, joint issues, and postpartum care.

Shanghai United Imaging Healthcare Co Ltd provides customers with high-performance medical imaging equipment, radiotherapy products, life science instruments, and medical digitalization and intelligent solutions. The company’s products include MRI systems, CT scanners, X-ray imaging equipment, molecular imaging systems, radiotherapy linear accelerators, and life science instruments.

Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.

Noom is a digital health platform combining psychology, AI, and human coaching for wellness goals including weight management, diabetes prevention, and stress reduction. New York City-headquartered, it secured grants from the National Institutes of Health and became the first mobile app certified by the Centers for Disease Control for diabetes prevention. Noom serves millions via app-based programs with behavioral tracking and virtual coaching sessions. Recognized by Inc and Fortune for workplace culture, it operates globally with personalized nutrition and habit-building modules.

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Hippocratic AI is a San Francisco-headquartered developer of large language models optimized for non-diagnostic healthcare interactions. Its platform deploys AI agents for tasks like preoperative education, discharge instructions, and chronic disease follow-ups via phone or text. Built on a multi-agent architecture with clinician oversight, the system includes an agent marketplace for specialties such as cardiology and oncology. Health systems integrate agents into workflows for patient outreach and triage support.

Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.